Amgen combined its R&D and AI functions under a single executive, James Bradner, in a sweeping leadership restructuring. The company also appointed a new CTO, embedding AI governance at the top of its research hierarchy.
Big Pharma is moving AI from pilot programs to organizational infrastructure. Amgen's restructuring is the clearest signal yet: AI is no longer housed in a separate technology department but fused into research leadership itself.
AI-native biotech Rakovina Therapeutics presented preclinical data at the AACR 2026 Annual Meeting from two programs built on generative AI platforms.1 One targets dual ATR-mTOR inhibition, a combination approach historically constrained by toxicity. The second focuses on CNS-penetrant oncology — designing compounds engineered to cross the blood-brain barrier.1
"Brain metastasis represents one of the most urgent and challenging frontiers in oncology," said Kazuko Matsuda.2 Rakovina's AI platform directly attacks this problem, designing molecules that bypass CNS penetrance failures and reduce combination toxicity burdens.1
Revolution Medicines presented preclinical data on RM-055 at AACR 2026.3 RM-055 is a mutant-targeted RAS inhibitor designed for KRAS G12 mutations. In vivo, RM-055 preferentially suppressed RAS pathway activation in KRAS G12 mutant tumors over normal tissues. That selectivity suggests an enhanced therapeutic window and more flexibility for combination regimens.3
Generative AI is tackling three persistent drug design failures: poor CNS penetrance, off-target toxicity, and limited mutant selectivity. These are not incremental improvements — they are engineering around the specific reasons earlier drug classes failed.
A crowded 2026 FDA regulatory calendar is sharpening investor focus on AI-designed pipelines. Multiple near-term binary readouts are expected across oncology programs.
The shift is structural, not cyclical. When a major pharma company reorganizes its entire R&D function around AI leadership, the technology has moved from supporting science to defining research strategy.
Sources:
1 Rakovina Therapeutics Inc., April 22, 2026, globenewswire.com
2 Kazuko Matsuda / MediciNova, Inc., April 27, 2026, globenewswire.com
3 Dr. Islam Mohamed, April 21, 2026, finance.yahoo.com